Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

IFNb/LPS activates convergence of inflammatory gene expression patterns between adipocytes and myeloid cells.

ABSTRACT: IFNb/LPS activates convergence of inflammatory gene expression patterns between adipocytes and myeloid cells.

PROVIDER: PRJNA433230 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR6677962.fastq.gz	Fastqsanger.gz
	SRR6677963.fastq.gz	Fastqsanger.gz
	SRR6677964.fastq.gz	Fastqsanger.gz
	SRR6677965.fastq.gz	Fastqsanger.gz
	SRR6677966.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

IFNb/LPS activates convergence of inflammatory gene expression patterns between adipocytes and myeloid cells.

Project description:We examined the transciptomic changes to primary adipocytes resulting from exposure to IFNb and/or LPS, in order to define the mechanisms driving adipocyte inflammatory capacity and resulting transcriptomic convergence with iinflammatory myeloid cells. Inguinal adipose tissue was obtained from 8 weeks old aged male C57BL/6 mice and stromal vascular fraction was maximally differentiated into primary adipocytes. Cultured cells were treated with IFNb (200U/ml) or saline for 3 hours and thereafter with LPS (100ng/ml) or saline for 4 hours and then submitted for RNA-sequencing. Results: We mapped approximately 20 million reads per sample to the mm10 genome, and analyzed all transcripts with >3 reads in 100% of at least one experimental condition.

2019-02-06 | GSE110236 | GEO

Pharmacogenomics of IFNb therapy

Project description:This experiment set is used for the manuscript entitled: Pharmacogenomics of Interferon-b therapy in multiple sclerosis: Baseline IFN signature determines pharmacological differences between patients. In this study we generated and analyzed pre- and post- IFNb treatment gene expression patterns of RRMS patients with the aim of identifying pre-existing and/or drug-induced signatures that will allow us to make predictions on the expected pharmacological effects of IFNb treatment. We show that the expression level of IFN response genes prior to treatment, determines the pharmacological differences between patients with MS at the molecular level. A group of 16 Dutch patients (10 females and 6 males) with clinically definite relapsing-remitting MS was recruited from the outpatient clinic of the MS Centre Amsterdam. Mean age at start of IFNb therapy is 40.6 +/- 7.7, mean EDSS is 2.3 +/- 1.3 (range 1-6). Blood samples were obtained just before treatment and 1 month after start of the therapy. Patients received Avonex, Betaferon, Rebif 22 or Rebif 44. A compound treatment design type is where the response to administration of a compound or chemical (including biological compounds such as hormones) is assayed. Compound Based Treatment: Before and 1 month after IFNb therapy Keywords: compound_treatment_design Complex

2008-04-01 | E-GEOD-10655 | biostudies-arrayexpress

Pharmacogenomics of IFNb therapy

2008-04-01 | GSE10655 | GEO

Impact of MEM40 and IFNB on human DC activation markers

Project description:To determine the impact of MEM40 and IFNB on normal human donor monocyte-derived DCs (Mo-DCs) phenotype, we used an experimental design where human A549 lung cancer cells were first infected with Ad-Null or adenoviruses expressing human IFNB, MEM40 or MEM40 + IFNB, followed by removal of virus-containing supernatant and co-culture with Mo-DCs. We used the above design followed by sorting of MHC-II+ CD11c+ cells for bulk RNA-sequencing.

2023-02-13 | GSE223342 | GEO

Gene-profile comparison of wt and Ifnb–/– cerebellar granular neurons

Project description:Interferon-b (IFN-b) belongs to the type I interferon family of cytokines and via binding to its receptor, interferon-a/b-receptor (IFNAR), it exerts immunoregulatory effects such as anti-viral and anti-inflammatory properties, and clinical benefits for patients with the CNS disease multiple sclerosis. To compare differentially regulated genes in neurons of interferon-beta knock out mice (Ifnb–/–), we conducted a microarray analysis on cerebellar granular neurons (CGNs) from wt (Ifnb+/+) and Ifnb-/- mice with or without treatment with recombinant IFN-b.

2015-10-08 | GSE63815 | GEO

The Cdkn2a gene product ARF is a critical regulator of IFNb mediated Lyme arthritis

Project description:Lyme disease is caused by infection with Borrelia burgdorferi, with a spectrum of clinical disorders. Murine studies with B6 and C3H mice have demonstrated that genetic differences in the host response play an essential role in regulating the severity of Lyme arthritis. C3H mice generate a robust induction of type I IFN response in joint tissue at one week of infection which leads to severe Lyme arthritis at 4 weeks post-infection, while B6 mice develop mild disease without a type I IFN profile. We used a forward genetic approach and identified B. burgdorferi arthritis- associated locus 1 (Bbaa1) on Chr4, which includes type I IFN cluster. B6.C3-Bbaa1 congenic mice display more severe Lyme arthritis than B6 mice. The blocking of type I IFN receptor and the IFNb subtype in Bbaa1 mice suppressed arthritis back to B6 level, so we concluded the Bbaa1 locus intrinsically controls IFNb production, and the differential expression of IFNb controls the severity of Lyme arthritis. However, the IFNb genes of C3H and B6 mice are identical, prompting focus on other genetic factors within the Bbaa1 locus as regulators of IFNb. Reciprocal radiation chimeras between B6.C3-Bbaa1 and B6 mice revealed myeloid cells in the joint tissue as IFNb initiators. Advanced congenic lines were generated to reduce the genetic contribution from C3H Bbaa1 region. RNA-seq of bone marrow-derived macrophages (BMDMs) from B6 and advanced interval specific recombinant congenic lines, ISRCL3 and ISRCL4, revealed novel candidates that may regulate Ifnb. In this study, we identify the Cdkn2a gene encoded ARF as a critical regulator of IFNb mediated Lyme arthritis, and investigate mechanistic interactions that modulate IFNb expression in Lyme arthritis development.

2022-02-17 | GSE181071 | GEO

Transcriptome profiling of primary murine fibroblast response to IFNB with or without prior Drosha depletion

Project description:To assess the impact of Drosha on the response to IFNB

2017-06-28 | GSE96889 | GEO

Effects of FTY720/IFNb on astrocytes

Project description:Combinatorial FTY720/IFNb induces protective factors in astrocytes

| PRJEB48316 | ENA

Single-cell RNA-seq of dermal fibroblasts (5 human individuals - IFNB stimulation)

Project description:Single-cell RNA-seq of human dermal fibroblasts, stimulated with IFNB 1000 IU for 2 or 6 hours, and profiled using the SmartSeq2 protocol.

2018-07-16 | E-MTAB-7051 | biostudies-arrayexpress

Transcriptomics effects of IFNb and IFNg stimulation on murine cancer cell lines

Project description:To measure the transcriptomic changes in response to IFNb and IFNg stimulation, we collected RNAseq of various cell lines that were stimulated or unstimulated by interferon for 48 hours

2022-08-01 | GSE206443 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data